Dermatologic Therapy最新文献

{"title":"Effect of Night Peeling With Azelaic Acid on Mature Facial Skin Parameters After 28 Days of Use: Preliminary Report","authors":"M. Drozdova-Statkevičienė,&nbsp;R. Rauluševičienė","doi":"10.1155/dth/9941546","DOIUrl":"https://doi.org/10.1155/dth/9941546","url":null,"abstract":"<div>\u0000 <p>The aim of this study was to determine the effect of night peeling with azelaic acid (AA) on the parameters of mature facial skin after 28 days of use. The sample consisted of 28 participants (six participants did not complete the study for reasons unrelated to cosmetic intolerance), aged 40–68 years old, including both men and women, with dry and/or normal skin types, closed comedones, and visible signs of aging. The study lasted 28 days, during which all participants were evaluated before and after the treatment with the night peeling containing AA. The results showed that not all parameters changed significantly. Significant changes was observed in the skin moisture level (increased by 4%), skin elasticity (improved by 11%), and wrinkle length (reduced by 4%). In addition, it reduced wrinkle count by an average of 15%, wrinkle volume by an average of 8%, and wrinkle area by an average of 5%. These findings indicate a successful response to the night peeling treatment with AA. However, the study was relatively small in size and could be extended to include more subjects and investigate the use of the product over a longer period of time.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9941546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Real-World Safety Profile of Secukinumab Assessed Through a 9-Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study","authors":"Elena Ippoliti,&nbsp;Gennaro Marco Falco,&nbsp;Tiago Torres,&nbsp;Eleonora De Luca,&nbsp;Clara De Simone,&nbsp;Giacomo Caldarola,&nbsp;Augusta Ortolan,&nbsp;Arianna Guaita,&nbsp;Andrea Chiricozzi,&nbsp;Giusy Peluso,&nbsp;Ketty Peris,&nbsp;Maria Antonietta D’Agostino","doi":"10.1155/dth/9618241","DOIUrl":"https://doi.org/10.1155/dth/9618241","url":null,"abstract":"<div>\u0000 <p>Secukinumab is a biologic agent known for its durable efficacy in chronic plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Monitoring the safety of secukinumab is a priority to ensure its long-term usage. We aimed to provide an extended safety assessment of secukinumab treatment in a real-world setting. This bicentric observational study enrolled 332 patients with PsO, PsA and AS who received subcutaneous injections of secukinumab for up to 9 years. Adverse events (AEs) were reported annually as exposure-adjusted incidence rates (EAIRs) per 100 patient-years (pt-y). The total secukinumab exposure was 1129 pt-y. The retention rate was 73%, with 16 (4.8%) of patients discontinuing due to AEs. Despite most AEs being reported within the first 2 years, their incidence was low and decreased over time. The EAIR of any AEs was the highest in the initial 6 months (32.72/100 pt-y), followed by year 1 (7.62/100 pt-y), and year 2 of treatment (3.01/100 pt-y). Common AEs included respiratory and urinary tract infections, candidiasis, and diarrhoea. Secukinumab showed sustained safety over an extended 9-year treatment period, supporting its use for the long-term management of these immune-inflammatory disorders.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9618241","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Controlled Study of the Efficacy of a Topical Antifungal, Antimicrobial, Anti-Inflammatory, and Antiseborrheic Cream in Treating Mild to Moderate Facial Seborrheic Dermatitis","authors":"Kridipop Charoenchaipiyakul,&nbsp;Patcharapong Rujirawan,&nbsp;Nopadon Noppakun,&nbsp;Yuda Chongpison,&nbsp;Chanat Kumtornrut","doi":"10.1155/dth/8887280","DOIUrl":"https://doi.org/10.1155/dth/8887280","url":null,"abstract":"<div>\u0000 <p>Seborrheic dermatitis (SD) presents treatment challenges due to its complex pathogenesis. A nonsteroidal cream (NSC) with antifungal, antimicrobial, anti-inflammatory, and antiseborrheic properties containing piloctone olamine, biosaccharide gum-2, stearyl glycyrrhetinate, and zinc PCA has shown promise in previous studies with the design that lacked control groups and demographic diversity. To validate its efficacy, this randomized, assessor-blinded, controlled trial included 50 Thai subjects with mild-to-moderate facial SD. Participants were randomized 1:1 to apply either NSC or a hydrophilic cream (control) twice daily for 8 weeks. Assessments at week (W) 0, 4, 8, and 12 (4 weeks posttreatment) included severity scores (mSDASI), Investigator Global Assessment (IGA), pruritus, and skin biophysics (erythema index, hydration, TEWL, and sebum levels). The use of triamcinolone acetonide 0.02% cream as rescue medication was recorded. Both NSC (<i>n</i> = 25) and control (<i>n</i> = 25) groups showed clinical improvement from W4, peaking at W8 and continuing to W12. The NSC group’s mSDASI significantly differed from controls at W8 (<i>p</i> = 0.043). The proportion of subjects achieving successful IGA (&gt; 80% improvement) was significantly higher in the NSC group at W8 (44% vs. 16%, <i>p</i> = 0.048). NSC also significantly reduced erythema index at all visits and sebum levels at W4, with lower trends toward pruritus and rescue medication use during treatment. No adverse effects were reported. Overall, NSC demonstrated positive therapeutic effects for mild to moderate facial SD in Southeast Asians, highlighting its potential as a treatment option.</p>\u0000 <p><b>Trail Registration:</b> Thai Clinical Trials Registry: TCTR20230811003</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8887280","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining Recruitment and Retention Strategies in Hidradenitis Suppurativa Clinical Trials: A Cross-Sectional Study","authors":"Jeanie Marchbanks,&nbsp;Eddy Bagaruka,&nbsp;Merhawit Ghebrehiwet,&nbsp;Andrew Wilson,&nbsp;Josh Autaubo,&nbsp;Payton Clark,&nbsp;Chase Pitchford,&nbsp;Alicia Ito Ford,&nbsp;Matt Vassar","doi":"10.1155/dth/9974685","DOIUrl":"https://doi.org/10.1155/dth/9974685","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> To ensure equitable and successful treatment outcomes for hidradenitis suppurativa (HS), the recruitment and retention of diverse participants in clinical trials is critical. However, current approaches may neglect under-represented populations, potentially limiting the result application.</p>\u0000 <p><b>Objective:</b> This study aimed to evaluate existing recruitment and retention strategies in HS trials, identifying gaps and proposing methods to improve inclusivity and participant retention.</p>\u0000 <p><b>Methods:</b> We conducted a cross-sectional analysis of 36 HS clinical trials from January 2018 to December 2023, following PRISMA guidelines. Trial characteristics and specific recruitment/retention approaches were assessed through data extraction and Stata 18 SE statistical analysis.</p>\u0000 <p><b>Results:</b> Of the 36 trials, 18/36 (50.0%) reported use of specific retention strategies, while 1/36 (2.8%) of the trials documented recruitment strategies for under-represented groups. Diversity goals were also unreported in recruitment processes. Most trials (63.9%) received industry funding, and therapeutic intervention was the most common treatment type (97.2%).</p>\u0000 <p><b>Limitations:</b> Only articles from 2018 to 2023 were analyzed, limiting the finding generalizability over broader timeframes.</p>\u0000 <p><b>Conclusion:</b> This study reveals significant gaps in recruitment/retention strategies within HS trials, which is important for enhancing result relevance and inclusivity, particularly among historically marginalized populations. Implementing specific approaches and innovative methods is critical for improving HS treatment efficacy and reducing health inequities.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9974685","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143914450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis","authors":"Manami Takahashi-Watanabe,&nbsp;Taku Fujimura,&nbsp;Emi Yamazaki,&nbsp;Ryo Amagai,&nbsp;Kenta Oka,&nbsp;Yumi Kambayashi,&nbsp;Maki Ozawa,&nbsp;Tomoko Chiba,&nbsp;Mayuko Onodera-Amagai,&nbsp;Toshiya Takahashi,&nbsp;Yoshihide Asano","doi":"10.1155/dth/6603966","DOIUrl":"https://doi.org/10.1155/dth/6603966","url":null,"abstract":"<div>\u0000 <p>Mycosis fungoides (MF) is an indolent form of cutaneous T-cell lymphoma. Its early lesions are important to be distinguished from atopic dermatitis (AD) because of their similar immune microenvironment. We have previously demonstrated that several chemokines are involved in the pathogenesis of advanced MF. Therefore, we sought to comprehensively analyze the changes in the immune environment during the advanced phase of MF by focusing on serum cytokines and chemokines and to identify potential biomarkers for the early detection of the transition to the advanced phase of MF. Sera from 11 cases of advanced-stage MF, 16 cases of mild AD (median EASI score = 5.75), 16 cases of severe AD (median EASI score = 28.1), and 21 healthy volunteers were analyzed using the Bio-Plex 40 multiplex immunoassay system. The results revealed significant increases in immunosuppressive macrophage-related factors (IL-4, MIF, CCL3) in MF patients compared to those with AD and healthy controls. In contrast, IL-2, CCL1, CCL7, CCL21, CCL25, and CCL26 were significantly increased in severe AD patients compared to MF patients and healthy controls. Our findings suggest that several chemokines and cytokines contribute to an immunosuppressive environment favorable for tumor growth, distinguishing MF from AD. Moreover, T-cell proliferation and migration factors, which are mainly involved in maintaining inflammation, are elevated in severe AD compared to MF. In addition to elucidating the differences in the pathogenesis of these diseases, these factors may be important in the differential diagnosis of early MF and AD. Further studies are warranted to confirm these findings.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6603966","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143900921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Safety Profile of Apremilast in Elderly Patients Same With That in Young and Middle-Aged Patients? A Real-World Disproportionality Analysis of the FDA Adverse Event Reporting System","authors":"Chenyang Yu,&nbsp;Jinxin Qi,&nbsp;Wei Yan,&nbsp;Xian Jiang","doi":"10.1155/dth/8851158","DOIUrl":"https://doi.org/10.1155/dth/8851158","url":null,"abstract":"<div>\u0000 <p><b>Background and Objective:</b> Elderly individuals face heightened risks of infections, thrombosis, cardiovascular issues, and neoplasms, necessitating increased vigilance regarding adverse drug events (ADEs). The safety of apremilast in elderly patients has not been adequately explored in clinical trials. This study was to evaluate the safety profile of apremilast in young and middle-aged patients and elderly patients separately, through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS).</p>\u0000 <p><b>Methods:</b> Reports in the FAERS from the third quarter of 2014 to the second quarter of 2023 were collected and analyzed. Disproportionality analyses (the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms) were employed to quantify the ADE signals of apremilast in the age groups of 18–65 years and over 65 years.</p>\u0000 <p><b>Results:</b> After data cleaning, a total of 54,926 and 14,156 ADE reports were retrieved, with 66 and 61 ADE signals identified in young and middle-aged patients and in elderly patients, respectively. Several unexpected ADE signals not listed in the drug labeling information were detected, including pericarditis, increased cholesterol levels, liver injury, postoperative thrombosis, serum calcium, and parathyroid abnormalities. Furthermore, weight loss, psychiatric abnormalities, and infections in particular sites (ear, bursa mucosa, and central nervous system) were more significant in elderly patients.</p>\u0000 <p><b>Conclusions:</b> The study indicated several unexpected ADEs through disproportionality analysis and highlighted unique safety features in the elderly group. These findings may assist clinicians in managing psoriasis with apremilast.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8851158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixekizumab Restores Clinical Response in Patients With Hidradenitis Suppurativa After Secondary Loss of Effectiveness From Adalimumab: Results From a Retrospective Analysis of a Case Series","authors":"Caroline Hilbring,&nbsp;Matthias Augustin,&nbsp;Gefion Girbig,&nbsp;Armin Fatehi,&nbsp;Natalia Kirsten","doi":"10.1155/dth/5597039","DOIUrl":"https://doi.org/10.1155/dth/5597039","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Hidradenitis suppurativa (HS) is a severe chronic inflammatory skin disease with a high burden of those affected. The tumor necrosis factor alpha (TNF-α)-inhibitor adalimumab was the first approved biologic in 2015, followed by secukinumab in 2023 and just recently, as of July 2024, the so far only selective dual IL-17A/F-inhibitor bimekizumab (Kimball et al. 2023). Analog to psoriasis treatment, there is still a strong need for further drug therapy options in case of primary nonresponse or secondary loss of effectiveness.</p>\u0000 <p><b>Objectives:</b> The study aim was to observe the effectiveness of ixekizumab in routine care for HS.</p>\u0000 <p><b>Methods:</b> We performed a retrospective analysis of structured data from ten patients with HS, treated with ixekizumab in 2019, after a secondary loss of effectiveness under adalimumab, at a time when adalimumab was still the only approved biologic for HS in Germany. Clinical response was measured using the International Hidradenitis Suppurativa Severity Score System (IHS4) and quality of life was assessed using the Dermatology Life Quality Index (DLQI) at baseline (week 0) and 16 weeks after the initiation of treatment.</p>\u0000 <p><b>Results:</b> Nine out of ten patients were female, mean age: 39.7 ± 11.0 years. The average IHS4 score decreased from 13.6 in week 0 to 9.6 in week 16. Three patients did not respond to treatment. DLQI resulted in an average decline of almost four points from 11.7 (week 0) to 7.8 (week 16).</p>\u0000 <p><b>Conclusions:</b> This case series indicates that a major proportion of patients with HS being treatment failures to adalimumab still respond to ixekizumab. Further studies with a larger study population are necessary to assess the long-term effectiveness and safety of ixekizumab in HS patients.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5597039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Diluted Calcium Hydroxyapatite Filler for Neck Rejuvenation: A Pilot Study on Single-Session, Short-Term Outcomes","authors":"Kui Young Park","doi":"10.1155/dth/1621113","DOIUrl":"https://doi.org/10.1155/dth/1621113","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Calcium hydroxyapatite (CaHA) fillers are widely used in esthetic medicine for skin rejuvenation; however, their efficacy and safety for neck rejuvenation remain underexplored.</p>\u0000 <p><b>Objective:</b> To evaluate the clinical efficacy and safety of a diluted CaHA filler for improving skin barrier function, hydration, elasticity, and wrinkle severity in the neck.</p>\u0000 <p><b>Methods:</b> This 4-week prospective, single-center pilot study involved 10 volunteers aged 19–70 years with a horizontal neck wrinkle severity (HNWS) score of 2 or higher. A total of 4.8 mL of CaHA filler (VoLassom) mixed with normal saline (1:2 ratio) was injected into the subdermal layer of the neck using a 28-gauge needle across 24 points (three horizontal lines and eight points per line). Clinical outcomes, including transepidermal water loss (TEWL), skin hydration, elasticity, and HNWS, were assessed at baseline and at 2 and 4 weeks after treatment.</p>\u0000 <p><b>Results:</b> Nine participants completed the study. TEWL decreased significantly from 8.07 ± 1.53 g/m²/h at the baseline to 6.11 ± 2.17 g/m²/h at week four (<i>p</i> = 0.001), reflecting improved skin barrier function. Skin hydration increased from 57.72 ± 7.17 AU at the baseline to 64.78 ± 4.27 AU at week 4 (<i>p</i> = 0.01), and elasticity parameters (R2, R5, and R7) showed significant improvements (<i>p</i> &lt; 0.05). The HNWS score decreased from 2.44 ± 0.53 at the baseline to 1.00 ± 0.00 at week 4. No significant adverse events were observed.</p>\u0000 <p><b>Conclusion:</b> Diluted CaHA filler is a safe and effective option for neck rejuvenation, significantly improving skin barrier function, hydration, elasticity, and wrinkle severity within a short observational period.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1621113","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Punch Excision Combined With Superficial X-Ray for the Treatment of Keloids: A Single-Center Retrospective Study","authors":"Junyou Zheng,&nbsp;Fang Fang,&nbsp;Wenbo Bu","doi":"10.1155/dth/4327219","DOIUrl":"https://doi.org/10.1155/dth/4327219","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Keloid management remains a challenge for clinicians. Recently, punch excision and photoelectric technology have demonstrated promising clinical applications for managing keloids; however, few studies have examined the efficacy and safety of punch excision combined with superficial X-ray for treating keloids.</p>\u0000 <p><b>Objective:</b> To investigate the efficacy and safety of punch excision combined with superficial X-ray for treating keloid.</p>\u0000 <p><b>Methods:</b> In this retrospective study, we analyzed the clinical records of 60 patients with keloid scars who underwent punch excision combined with superficial X-ray at our hospital, from April 2020 to April 2023. The Vancouver Scar Scale (VSS) and Patient and Observer Scar Assessment Scale (POSAS) 2.0 Patient Scale serve as the primary assessment tools to evaluate all patients, both prior to the initial treatment and one year after the completion of therapy. SPSS software was used for statistical analysis to assess keloid improvement.</p>\u0000 <p><b>Results:</b> In the 60 patients with keloids, varying degrees of improvement were observed. The VSS and POSAS scores recorded 1 year after treatment were significantly lower than the pretreatment scores (<i>p</i> &lt; 0.001). No severe adverse reactions were observed during treatment.</p>\u0000 <p><b>Conclusion:</b> The combination of punch excision and superficial X-ray demonstrated a notable therapeutic effect on keloids without evident adverse reactions, offering a safe and effective option for patients with keloids.</p>\u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2400094289</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4327219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143861644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural History and Prognostic Factors of Chronic Urticaria in Children Aged < 2 Years: A Single-Centered, Real-World, and Retrospective Study","authors":"Chun-Xiao Li,&nbsp;Hua-Guo Li,&nbsp;Bei-Bei Zhang,&nbsp;Yun Huang,&nbsp;Bei-Ming Wang,&nbsp;Yi-Hang Shen,&nbsp;Xiao-Xiao Wang,&nbsp;Wei-Qin Yang,&nbsp;Yan Gu,&nbsp;Yi-Feng Guo,&nbsp;Hui Zhang","doi":"10.1155/dth/1564070","DOIUrl":"https://doi.org/10.1155/dth/1564070","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> To date, a limited number of studies have reported on the natural course and prognostic factors of chronic urticaria (CU) among children aged &lt; 2 years.</p>\u0000 <p><b>Objective:</b> In this study, we delineated the characteristics and natural history of CU in children aged &lt; 2 years, with an additional aim of identifying prognostic factors closely associated with CU.</p>\u0000 <p><b>Methods:</b> This study included children aged &lt; 2 years who had CU between May 2019 and June 2023. The clinical data and laboratory results of these children were retrieved from their medical records or through telephone interviews.</p>\u0000 <p><b>Results:</b> The study population comprised 111 children with a median age of 16.30 (0.3–24) months at onset. Remission rates at 6, 12, and 36 months after the onset of CU were 36.08%, 51.55%, and 77.32%, respectively. After the sex and age at onset were adjusted, multivariate regression analysis revealed that allergic conjunctivitis was a risk factor for CU (OR_adjusted = 5.14 [95% CI, 1.03–28.52]).</p>\u0000 <p><b>Conclusion:</b> The course of CU in children aged &lt; 2 years is relatively short, with most children having a favorable outcome. Allergic conjunctivitis serves as a risk factor for CU in this age group.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1564070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}